

# **Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), By Type (Drugs, Preventive Vaccines, Oxygen Therapy), By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others) Region and Competition**

<https://marketpublishers.com/r/P410D09AEC2FEN.html>

Date: February 2024

Pages: 184

Price: US\$ 4,900.00 (Single User License)

ID: P410D09AEC2FEN

## **Abstracts**

Global Pneumonia Therapeutics Market was valued at USD 2.21 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.16% through 2029. The global pneumonia therapeutics market is a dynamic and crucial segment of the pharmaceutical and healthcare industry, focused on combating a prevalent and life-threatening respiratory infection known as pneumonia. Pneumonia, characterized by inflammation in the air sacs of the lungs, can be caused by various pathogens, including bacteria, viruses, and fungi. It poses a significant public health challenge worldwide, affecting individuals of all age groups but particularly impacting the elderly, children, and those with weakened immune systems. As a result, the market for pneumonia therapeutics has witnessed substantial growth and innovation in recent years.

The market is primarily driven by the rising incidence of pneumonia, fueled by factors such as aging populations, increased antibiotic resistance, and the spread of infectious

diseases. This has led to a growing demand for effective treatment options. Pneumonia therapeutics encompass a wide range of pharmaceuticals, including antibiotics, antivirals, and supportive care medications. The advent of novel antimicrobial agents and advancements in diagnostic techniques have expanded treatment options, leading to a surge in research and development activities.

Furthermore, the COVID-19 pandemic has accelerated the market's growth, as severe cases of COVID-19 often manifest with pneumonia-like symptoms, driving the demand for pneumonia therapeutics and related healthcare services. Vaccination efforts and public health campaigns also play a pivotal role in preventing pneumonia, indirectly impacting the market.

## Key Market Drivers

### Rising Pneumonia Incidence

The escalating incidence of pneumonia is a key driver behind the growth of the global pneumonia therapeutics market. Pneumonia, a common respiratory infection, affects individuals of all ages and continues to be a significant public health concern. Several factors contribute to the rising incidence of pneumonia, making effective therapeutics a necessity. First, the aging population, especially in developed countries, is at an increased risk of pneumonia due to weakened immune systems and age-related health conditions. This demographic shift has led to a surge in pneumonia cases among the elderly, resulting in a higher demand for treatment options.

The emergence of antibiotic-resistant bacteria poses a significant challenge in treating pneumonia. Antibiotic resistance has made it more difficult to combat bacterial pneumonia effectively, necessitating the development of novel antimicrobial agents. Pharmaceutical companies are investing in research and development to create more potent antibiotics, addressing the increasing prevalence of drug-resistant strains and further propelling the pneumonia therapeutics market.

Additionally, the persistence of infectious diseases and the global spread of various pathogens contribute to the higher incidence of pneumonia. These infectious agents, including bacteria and viruses, can cause both community-acquired and hospital-acquired pneumonia. The ongoing threat of outbreaks and pandemics, such as the COVID-19 pandemic, underscores the importance of effective pneumonia treatment and prevention, thus driving market growth.

The rising incidence of pneumonia is a critical factor boosting the global pneumonia therapeutics market. The aging population, antibiotic resistance, and the continued prevalence of infectious diseases are major contributors to this trend. These factors highlight the need for ongoing research, innovation, and development in the field of pneumonia therapeutics to meet the growing demand and provide effective treatment options for individuals suffering from this potentially life-threatening respiratory infection.

### Advances in Antimicrobial Agents

Advances in antimicrobial agents are playing a pivotal role in boosting the global pneumonia therapeutics market. Pneumonia, a respiratory infection caused by various pathogens, including bacteria and viruses, has been a persistent healthcare concern. However, the development of innovative antimicrobial agents has significantly improved the effectiveness of pneumonia treatment, thereby propelling market growth.

One of the most critical drivers is the continuous evolution of antibiotic therapy. Over time, bacteria have developed resistance to many commonly used antibiotics, creating a challenge in treating bacterial pneumonia effectively. To address this issue, researchers have been actively engaged in the discovery and development of new antibiotics that are more potent against drug-resistant strains. These new antimicrobial agents are not only enhancing patient outcomes but also providing pharmaceutical companies with opportunities to introduce novel, effective products to the market.

Furthermore, the emergence of antiviral medications has significantly expanded the therapeutic options for viral pneumonia. Advancements in antiviral drugs have allowed for more targeted and efficacious treatment of viral pneumonia, including influenza and COVID-19, which are major contributors to pneumonia cases. The availability of antiviral agents with enhanced effectiveness has not only improved patient recovery but also broadened the scope of the pneumonia therapeutics market, addressing a wider spectrum of pathogens.

The development of combination therapies, involving both antibiotics and antiviral agents, is another noteworthy advancement. These combination treatments offer a multifaceted approach to tackling pneumonia, especially in cases where the causative agents may be mixed or where bacterial and viral co-infections occur. Such therapies have become a game-changer in pneumonia management, allowing for more precise and comprehensive patient care.

### Diagnostic Advancements

Diagnostic advancements have become a significant driving force behind the growth of the global pneumonia therapeutics market. Accurate and timely diagnosis is pivotal in ensuring the appropriate and effective treatment of pneumonia, and recent progress in diagnostic techniques is revolutionizing the way healthcare providers approach this respiratory infection.

One of the key diagnostic advancements is the utilization of molecular diagnostic methods, such as polymerase chain reaction (PCR) and nucleic acid tests. These techniques have greatly improved the precision and speed with which pneumonia can be diagnosed. Molecular diagnostics enable healthcare professionals to identify the specific causative agents of pneumonia, whether they are bacteria, viruses, or fungi, allowing for more targeted and tailored treatment regimens. This not only enhances patient outcomes but also helps in reducing the misuse of antibiotics, thus contributing to the global efforts to combat antimicrobial resistance.

Additionally, advancements in radiological imaging techniques, such as computed tomography (CT) scans and high-resolution chest X-rays, have played a crucial role in the diagnosis and assessment of pneumonia. These technologies offer a detailed view of the lungs, helping clinicians identify the extent and severity of lung involvement. As a result, physicians can make more informed decisions about the appropriate course of treatment, including the need for hospitalization, oxygen therapy, or specific medications.

Point-of-care testing (POCT) has also gained prominence in the diagnosis of pneumonia, especially in primary care settings and resource-limited environments. Rapid diagnostic tests can identify pneumonia pathogens within minutes, enabling quicker initiation of appropriate treatment and reducing the time to diagnosis. This is particularly important in cases of severe or atypical pneumonia, where early intervention is critical.

Furthermore, telemedicine and digital health solutions have emerged as powerful tools for remote diagnosis and consultation, making it easier for patients to access medical expertise and receive timely evaluations. Telehealth applications allow healthcare professionals to remotely examine patients and prescribe necessary treatments promptly.

## Key Market Challenges

## Antibiotic Resistance

Antibiotic resistance stands as one of the foremost challenges in the global pneumonia therapeutics market, significantly impacting the efficacy of treatment options and posing a serious threat to public health. Pneumonia, a common and potentially life-threatening respiratory infection, is often caused by bacterial pathogens, and antibiotics have been a primary line of defense against these infections. However, the emergence and spread of antibiotic-resistant strains of bacteria are severely hindering the effectiveness of existing pneumonia treatments.

Antibiotic resistance occurs when bacteria develop mechanisms to withstand the effects of antibiotics, rendering these drugs less or entirely ineffective in treating bacterial infections. In the context of pneumonia, this poses a major problem, as timely and appropriate antibiotic treatment is essential to mitigate the severity of the disease. Several factors contribute to antibiotic resistance in the context of pneumonia, and they have significant implications for the global pneumonia therapeutics market:

The widespread use and sometimes misuse of antibiotics have accelerated the development of resistance. In many cases, antibiotics are prescribed without proper diagnostic confirmation of bacterial pneumonia. This overuse contributes to the selective pressure on bacteria, favoring the growth of resistant strains.

The development of new antibiotics has been slow in recent years, partly due to the high costs and challenges associated with researching and bringing new antibiotics to market. This limited pipeline of novel antibiotics further exacerbates the issue of antibiotic resistance in pneumonia treatment.

## Delayed Diagnosis

Pneumonia can present with a wide range of symptoms, some of which may overlap with other respiratory conditions. In some cases, patients may not display the classic signs of pneumonia, such as high fever, productive cough, and chest pain, leading to initial misdiagnosis or delayed recognition of the infection. The availability and accuracy of diagnostic tools can vary significantly across regions and healthcare settings. In resource-limited areas, access to advanced diagnostic tests, such as radiological imaging or molecular diagnostics, may be limited, leading to delays in diagnosis.

The severity of pneumonia can be underestimated, especially in cases where the patient's clinical condition does not immediately appear critical. This can lead to a delay

in initiating appropriate treatment, which can be crucial in preventing the progression of the disease to a more severe stage.

Pneumonia can be complicated by other respiratory conditions or co-infections, making diagnosis more challenging. In such cases, it may take longer to identify the underlying cause of the patient's respiratory distress.

Delayed diagnosis can result in delayed treatment initiation, leading to worsened patient outcomes. Pneumonia can progress rapidly, and every hour of delay in treatment can increase the risk of complications and mortality.

Prolonged hospital stays, more aggressive treatment regimens, and the need for intensive care due to delayed diagnosis can result in higher healthcare costs. Patients with severe pneumonia may require more extensive and expensive interventions.

The delayed diagnosis and treatment of pneumonia can strain healthcare resources, particularly in high-incidence areas or during outbreaks. Overburdened healthcare systems can impact the quality of care provided to pneumonia patients.

## Key Market Trends

### Advancements in Antibiotics and Antiviral Therapies

Advancements in antibiotics and antiviral therapies are playing a pivotal role in boosting the global pneumonia therapeutics market. Pneumonia, a respiratory infection often caused by bacteria and viruses, has witnessed significant progress in the development of more effective treatment options, thanks to ongoing innovations in antimicrobial agents.

One of the most notable trends in pneumonia therapeutics is the continuous development of novel antibiotics that are potent against drug-resistant bacterial strains. This breakthrough is particularly crucial as antibiotic resistance has become a formidable challenge in treating pneumonia. The emergence of these new antibiotics has enhanced the precision of treatment for pneumonia, ensuring that patients receive effective care, even when confronted with resistant pathogens.

In parallel, the evolution of antiviral medications has expanded the treatment options for viral pneumonia. As viral pneumonia can include infections like influenza and respiratory illnesses such as COVID-19, effective antiviral therapies have become a cornerstone in

the fight against these diseases. Antiviral advancements have not only improved patient outcomes but also broadened the scope of the pneumonia therapeutics market, allowing healthcare providers to address a wider spectrum of pathogens causing respiratory infections.

Furthermore, the trend of combination therapies, involving both antibiotics and antiviral agents, has gained prominence. This approach provides a multifaceted strategy to pneumonia management, enabling comprehensive treatment plans, especially in cases of bacterial and viral co-infections or mixed causative agents. The synergistic effects of combination therapies often result in better patient outcomes, emphasizing the evolving landscape of pneumonia treatment.

### Combination Therapies

Combination therapies are emerging as a significant driving force behind the growth of the global pneumonia therapeutics market. Pneumonia, a respiratory infection caused by various pathogens, often presents complex challenges in treatment, with mixed causative agents or bacterial and viral co-infections. In response to these challenges, combination therapies have gained prominence, providing a multifaceted approach to pneumonia management.

Pneumonia cases with mixed or resistant pathogens may not respond optimally to a single treatment approach. Combination therapies combine the strengths of different medications, providing a more comprehensive and effective treatment, particularly in severe or complicated cases.

Pneumonia can be caused by a variety of pathogens, and accurately identifying the causative agent can be challenging. Combination therapies do not rely on pinpointing the exact pathogen but rather offer a broad-spectrum approach, ensuring that patients receive effective treatment even when the specific agent is unknown.

The use of multiple agents with different mechanisms of action can help mitigate the development of antibiotic or antiviral resistance. By targeting pathogens through various pathways, combination therapies make it more challenging for them to adapt and become resistant.

Combination therapies can be tailored to individual patient needs, taking into account their clinical presentation, coexisting conditions, and the severity of pneumonia. This personalized approach optimizes patient care.

Clinical studies have shown that combination therapies often lead to better patient outcomes, including faster recovery, reduced complications, and shorter hospital stays.

## Segmental Insights

### Products and Services Insights

Based on the Infection Type, Community-acquired pneumonia (CAP) emerged as the dominant segment in the global market for Global Pneumonia Therapeutics in 2023. CAP is more prevalent than HAP or VAP. It affects a larger population, including individuals of all ages, from children to the elderly. The greater incidence of CAP results in a higher demand for pneumonia treatment options in both developed and developing regions. Many CAP cases can be managed on an outpatient or ambulatory care basis, which means that patients are often treated in non-hospital settings. This results in a substantial market demand for therapeutics that can be used outside of the hospital environment. CAP can be caused by various pathogens, including bacteria, viruses, and fungi. This diversity necessitates a range of pneumonia therapeutics to address the different etiologies, further fueling demand in the market.

## Type Insights

Based on the Type, Preventive Vaccines emerged as the dominant segment in the global market for Global Pneumonia Therapeutics Market in 2023. Drugs are the primary mode of treatment for pneumonia, whether it's community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). Antibiotics and antiviral medications are the cornerstone of pneumonia treatment, targeting the specific causative agents. The majority of pneumonia cases, especially CAP, are treated with drugs to eradicate the infection. Drug therapy for pneumonia is highly versatile. It can be adapted to address various pathogens, including bacteria, viruses, and fungi, which cause different types of pneumonia. This versatility allows healthcare providers to tailor treatment regimens based on the specific etiology, patient factors, and disease severity.

## Regional Insights

North America emerged as the dominant player in the Global Pneumonia Therapeutics Market in 2023, holding the largest market share. The region is a hub for pharmaceutical and biotechnology research and development. It is home to many leading



pharmaceutical companies and research institutions that actively invest in the development of innovative pneumonia therapeutics, including antibiotics, antiviral drugs, and vaccines. North America has stringent regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada that provide a rigorous but well-defined pathway for drug approval. This regulatory environment promotes the development and commercialization of new pneumonia treatments, ensuring their safety and efficacy. Pneumonia remains a significant healthcare concern in North America, especially among vulnerable populations such as the elderly, young children, and individuals with underlying health conditions. The region's aging population and the prevalence of comorbidities contribute to a continued high demand for pneumonia therapeutics.

### Key Market Players

Pfizer Inc.

AstraZeneca Plc.

Eli Lilly & company

F. Hoffmann-La Roche Ltd.

Viartis Inc.

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

Sun Pharmaceutical Industries Ltd.

Aurobindo Pharma

### Report Scope:

In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Pneumonia Therapeutics Market, By Infection Type:

Hospital-acquired Pneumonia [HAP]

Community-acquired Pneumonia [CAP]

Ventilator-associated Pneumonia [VAP])

Global Pneumonia Therapeutics Market, By Type:

Drugs

Preventive Vaccines

Oxygen Therapy

Global Pneumonia Therapeutics Market, By Drug Class:

Antibacterial Drugs

Antiviral Drugs

Antifungal Drugs

Global Pneumonia Therapeutics Market, By End User:

Hospitals and Clinics

Ambulatory Surgical Centers

Others

Global Pneumonia Therapeutics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

### Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumonia Therapeutics Market.

### Available Customizations:

Global Pneumonia Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

### Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET OUTLOOK

- 4.1. Market Size & Forecast
  - 4.1.1. By Value
- 4.2. Market Share & Forecast
  - 4.2.1. By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])
  - 4.2.2. By Type (Drugs, Preventive Vaccines, Oxygen Therapy)
  - 4.2.3. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)
  - 4.2.4. By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
  - 4.2.5. By Region

- 4.2.6. By Company (2023)
- 4.3. Market Map
  - 4.3.1. By Infection Type
  - 4.3.2. By Type
  - 4.3.3. By Drug Class
  - 4.3.4. By End User
  - 4.3.5. By Region

## **5. ASIA PACIFIC PNEUMONIA THERAPEUTICS MARKET OUTLOOK**

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Infection Type
  - 5.2.2. By Type
  - 5.2.3. By Drug Class
  - 5.2.4. By End User
  - 5.2.5. By Country
- 5.3. Asia Pacific: Country Analysis
  - 5.3.1. China Pneumonia Therapeutics Market Outlook
    - 5.3.1.1. Market Size & Forecast
      - 5.3.1.1.1. By Value
    - 5.3.1.2. Market Share & Forecast
      - 5.3.1.2.1. By Infection Type
      - 5.3.1.2.2. By Type
      - 5.3.1.2.3. By Drug Class
      - 5.3.1.2.4. By End User
  - 5.3.2. India Pneumonia Therapeutics Market Outlook
    - 5.3.2.1. Market Size & Forecast
      - 5.3.2.1.1. By Value
    - 5.3.2.2. Market Share & Forecast
      - 5.3.2.2.1. By Infection Type
      - 5.3.2.2.2. By Type
      - 5.3.2.2.3. By Drug Class
      - 5.3.2.2.4. By End User
  - 5.3.3. Australia Pneumonia Therapeutics Market Outlook
    - 5.3.3.1. Market Size & Forecast
      - 5.3.3.1.1. By Value
    - 5.3.3.2. Market Share & Forecast

- 5.3.3.2.1. By Infection Type
- 5.3.3.2.2. By Type
- 5.3.3.2.3. By Drug Class
- 5.3.3.2.4. By End User
- 5.3.4. Japan Pneumonia Therapeutics Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Infection Type
    - 5.3.4.2.2. By Type
    - 5.3.4.2.3. By Drug Class
    - 5.3.4.2.4. By End User
- 5.3.5. South Korea Pneumonia Therapeutics Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Infection Type
    - 5.3.5.2.2. By Type
    - 5.3.5.2.3. By Drug Class
    - 5.3.5.2.4. By End User

## **6. EUROPE PNEUMONIA THERAPEUTICS MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Infection Type
  - 6.2.2. By Type
  - 6.2.3. By Drug Class
  - 6.2.4. By End User
  - 6.2.5. By Country
- 6.3. Europe: Country Analysis
  - 6.3.1. France Pneumonia Therapeutics Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Infection Type
      - 6.3.1.2.2. By Type
      - 6.3.1.2.3. By Drug Class

- 6.3.1.2.4. By End User
- 6.3.2. Germany Pneumonia Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Infection Type
    - 6.3.2.2.2. By Type
    - 6.3.2.2.3. By Drug Class
    - 6.3.2.2.4. By End User
- 6.3.3. Spain Pneumonia Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Infection Type
    - 6.3.3.2.2. By Type
    - 6.3.3.2.3. By Drug Class
    - 6.3.3.2.4. By End User
- 6.3.4. Italy Pneumonia Therapeutics Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Infection Type
    - 6.3.4.2.2. By Type
    - 6.3.4.2.3. By Drug Class
    - 6.3.4.2.4. By End User
- 6.3.5. United Kingdom Pneumonia Therapeutics Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Infection Type
    - 6.3.5.2.2. By Type
    - 6.3.5.2.3. By Drug Class
    - 6.3.5.2.4. By End User

## **7. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast



- 7.2.1. By Infection Type
- 7.2.2. By Type
- 7.2.3. By Drug Class
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. North America: Country Analysis
  - 7.3.1. United States Pneumonia Therapeutics Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Infection Type
      - 7.3.1.2.2. By Type
      - 7.3.1.2.3. By Drug Class
      - 7.3.1.2.4. By End User
  - 7.3.2. Mexico Pneumonia Therapeutics Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Infection Type
      - 7.3.2.2.2. By Type
      - 7.3.2.2.3. By Drug Class
      - 7.3.2.2.4. By End User
  - 7.3.3. Canada Pneumonia Therapeutics Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Infection Type
      - 7.3.3.2.2. By Type
      - 7.3.3.2.3. By Drug Class
      - 7.3.3.2.4. By End User

## **8. SOUTH AMERICA PNEUMONIA THERAPEUTICS MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Infection Type
  - 8.2.2. By Type
  - 8.2.3. By Drug Class

- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. South America: Country Analysis
  - 8.3.1. Brazil Pneumonia Therapeutics Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Infection Type
      - 8.3.1.2.2. By Type
      - 8.3.1.2.3. By Drug Class
      - 8.3.1.2.4. By End User
  - 8.3.2. Argentina Pneumonia Therapeutics Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Infection Type
      - 8.3.2.2.2. By Type
      - 8.3.2.2.3. By Drug Class
      - 8.3.2.2.4. By End User
  - 8.3.3. Colombia Pneumonia Therapeutics Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Infection Type
      - 8.3.3.2.2. By Type
      - 8.3.3.2.3. By Drug Class
      - 8.3.3.2.4. By End User

## **9. MIDDLE EAST AND AFRICA PNEUMONIA THERAPEUTICS MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Infection Type
  - 9.2.2. By Type
  - 9.2.3. By Drug Class
  - 9.2.4. By End User
  - 9.2.5. By Country
- 9.3. MEA: Country Analysis

### 9.3.1. South Africa Pneumonia Therapeutics Market Outlook

#### 9.3.1.1. Market Size & Forecast

##### 9.3.1.1.1. By Value

#### 9.3.1.2. Market Share & Forecast

##### 9.3.1.2.1. By Infection Type

##### 9.3.1.2.2. By Type

##### 9.3.1.2.3. By Drug Class

##### 9.3.1.2.4. By End User

### 9.3.2. Saudi Arabia Pneumonia Therapeutics Market Outlook

#### 9.3.2.1. Market Size & Forecast

##### 9.3.2.1.1. By Value

#### 9.3.2.2. Market Share & Forecast

##### 9.3.2.2.1. By Infection Type

##### 9.3.2.2.2. By Type

##### 9.3.2.2.3. By Drug Class

##### 9.3.2.2.4. By End User

### 9.3.3. UAE Pneumonia Therapeutics Market Outlook

#### 9.3.3.1. Market Size & Forecast

##### 9.3.3.1.1. By Value

#### 9.3.3.2. Market Share & Forecast

##### 9.3.3.2.1. By Infection Type

##### 9.3.3.2.2. By Type

##### 9.3.3.2.3. By Drug Class

##### 9.3.3.2.4. By End User

## 10. MARKET DYNAMICS

### 10.1. Drivers

### 10.2. Challenges

## 11. MARKET TRENDS & DEVELOPMENTS

### 11.1. Recent Developments

### 11.2. Product Launches

### 11.3. Mergers & Acquisitions

## 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET: SWOT ANALYSIS

## 13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Product

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Pfizer Inc.
  - 14.1.1. Business Overview
  - 14.1.2. Company Snapshot
  - 14.1.3. Products & Services
  - 14.1.4. Financials (In case of listed)
  - 14.1.5. Recent Developments
  - 14.1.6. SWOT Analysis
- 14.2. AstraZeneca Plc.
- 14.3. Eli Lilly & company
- 14.4. F. Hoffmann-La Roche Ltd.
- 14.5. Viartis Inc.
- 14.6. Teva Pharmaceutical Industries Ltd.
- 14.7. Sanofi SA
- 14.8. Novartis AG
- 14.9. Sun Pharmaceutical Industries Ltd.
- 14.10. Aurobindo Pharma

## **15. STRATEGIC RECOMMENDATIONS**

## **16. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), By Type (Drugs, Preventive Vaccines, Oxygen Therapy), By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others) Region and Competition

Product link: <https://marketpublishers.com/r/P410D09AEC2FEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P410D09AEC2FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970